Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by Boomskidon Dec 23, 2022 2:05pm
92 Views
Post# 35190032

RE:RE:RE:RE:RE:RE:RE:Some Thoughts in Summary

RE:RE:RE:RE:RE:RE:RE:Some Thoughts in SummaryPoof, the optics over the next Q or 2 could be swell. These are patient people. They took over 18 months to set this up. 

I can't get over the question about where xB3 went in Rathjen's activities during that time. Why has xB3 virtually disappeared?

They may want Biodexa to appear to have value without xB3, xB3-001 and all the other xB3s, named and unnamed.

If you have another opinion about why xB3 pretty much disappeared over the last 18 months, let's hear it, because the predictions you're making about the next 2 or 3 quarters are meaningless unless we know where xB3 is and where it's going.

And, poof, the markets in the US and GB value the deal at less than CDN 4¢. That's in very sharp disagreement with you. That's a lot of market opinion.

It may not be permanent but that's what the market thinks right now.

JD Boomskid
<< Previous
Bullboard Posts
Next >>